Spravato® is an FDA-approved breakthrough treatment for treatment resistant major depressive disorder (TRD) in adults. It is an intranasal medicine, prescribed along with an oral antidepressant.

Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects.

Who Can Benefit from Spravato?

Spravato, an FDA-approved ketamine-based therapy, is a nasal spray that targets specific brain receptors to relieve symptoms. It treats adults with the following conditions:

Treatment-Resistant Depression (TRD)

Treatment-resistant depression is depression that does not improve with two or more antidepressants tried at adequate dosages and duration.

Major Depressive Disorder with Suicidal Ideations

If you have major depressive disorder and have expressed suicidal thoughts or behaviors, Spravato® nasal spray may be an appropriate next step in treatment.

How To Get Started

How To Get Started

Insurance Approval (1)

FAQ

Yes, Spravato (esketamine nasal spray) is generally covered by most insurance plans in the U.S., including Medicare and private insurers. However, coverage specifics can vary based on your insurance provider, plan type, and individual circumstances.

Yes, Spravato (esketamine) is now FDA-approved as a standalone treatment for adults with treatment-resistant depression (TRD).

Some of the common side effects of Spravato are dizziness, nausea, headache and can increase blood pressure.

Patients are not to eat for at least 2 hours before your treatment and are not to drink at least 30 minutes before your treatment.

Get Relief from Depression Today!

Book Your Appointment

Thank you for submitting your information. Our staff will contact you!